Does Poor Sleep Worsen Inflammation in Rheumatoid Arthritis and Heart Disease?

Research-informed explainer — last updated April 12, 2026

If you are taking a biologic for rheumatoid arthritis and still having flares, your medication may not be the problem. A growing body of research shows that sleeping fewer than 6 hours a night activates the same inflammatory signaling pathways that adalimumab, etanercept, and tocilizumab are designed to suppress — potentially undoing the effect of your treatment night after night. Rheumatologists and cardiologists rarely ask about sleep as a disease modifier. The evidence suggests they should.

This explainer draws on research from three rheumatologists in the Convene directory. Leslie Crofford at Vanderbilt University Medical Center conducted foundational work on cyclooxygenase biology and the hypothalamic-pituitary-adrenal (HPA) axis in inflammatory and pain conditions, including research connecting HPA perturbations to fibromyalgia and inflammatory signaling [1, 2]. Deepak Rao at Brigham and Women's Hospital has studied cytokine activity in RA synovial tissue and coronary artery infiltrating T cells, including the synergistic effects of IL-17 and IFN-gamma on vascular inflammation [3, 4]. Tuhina Neogi, Chief of Rheumatology at Boston Medical Center, helped define how RA disease activity is measured in clinical practice — including the growing recognition that fatigue and functional impairment belong alongside joint counts as outcome measures [5, 6].

How does poor sleep actually trigger inflammation?

The mechanism is not vague or theoretical. Sleep deprivation — even a single night of fewer than 6 hours — activates nuclear factor-kappa B (NF-kB), the master transcription factor that controls the body's inflammatory response. When NF-kB switches on, it drives production of IL-6, TNF-alpha, and IL-1 beta: the same cytokines at the center of RA pathology and cardiovascular inflammation.

These are not incidental findings. Biologic medications for RA work precisely by blocking these molecules. Adalimumab and etanercept neutralize TNF-alpha. Tocilizumab blocks the IL-6 receptor. If sleep deprivation is continuously re-activating NF-kB and driving new cytokine production, a biologic taken every two weeks is fighting against a daily inflammatory signal from disrupted sleep. Measurable elevations in IL-6 and CRP have been documented within 24 to 48 hours of a single night of short sleep in healthy adults — before any underlying disease enters the picture.

The COX connection: why NSAIDs keep losing ground

Leslie Crofford's work on cyclooxygenase biology helps explain why anti-inflammatory medications can feel like they are not working for some patients [1]. COX-1 and COX-2 enzymes are part of the same inflammatory cascade that NF-kB activates. NSAIDs like ibuprofen and naproxen work by inhibiting COX enzymes — but if sleep deprivation is continuously re-triggering the upstream NF-kB signal, the inflammatory cascade restarts as soon as the medication wears off.

Crofford's earlier research on HPA axis perturbations in fibromyalgia patients showed that dysregulation of the cortisol stress response — which is a well-documented consequence of chronic poor sleep — amplifies both pain sensitivity and inflammatory tone [2]. The HPA axis normally produces cortisol as a natural anti-inflammatory signal during the day. When sleep disruption blunts that cortisol response, the body loses one of its own brakes on inflammation. The result is a lower pain threshold and a higher baseline of inflammatory signaling, independent of disease activity per se.

What does this mean for rheumatoid arthritis specifically?

For patients with RA, the relationship between sleep and disease activity is bidirectional and self-reinforcing in the worst way.

Studies measuring disease activity with standard tools like the DAS28 (Disease Activity Score using 28 joint counts) and CDAI (Clinical Disease Activity Index) have found that patients with poor sleep quality score significantly higher — meaning more active disease — even after controlling for biologic use and other medications. Tuhina Neogi's work on RA disease activity measurement underscores why this matters: the ACR now recommends composite scores that include patient-reported outcomes like pain and function, not just tender and swollen joint counts [6]. When fatigue and functional impairment are measured, the contribution of sleep disruption to apparent disease activity becomes even more visible.

Deepak Rao's cytokine research adds a specific molecular layer. IL-17 and IFN-gamma — cytokines elevated in RA synovial tissue and, as his work showed, in coronary artery-infiltrating T cells — are also upregulated by sleep loss [3]. Sleep deprivation does not just cause nonspecific inflammation; it preferentially elevates the cytokines already doing damage in RA joints and cardiovascular tissue.

The feedback loop is genuinely difficult to break. Active RA causes pain, which disrupts sleep. Joint inflammation drives fatigue, which may lead to irregular sleep schedules. Night sweats from disease activity and some medications interfere with sleep architecture. Then poor sleep drives more inflammation, raising DAS28 scores and potentially triggering flares — which cause more pain and more disrupted sleep.

What about heart disease?

The cardiovascular connection is independent of RA. Short sleep duration — consistently defined as fewer than 6 hours per night — is an independent predictor of incident cardiovascular events in large population studies, even after adjusting for hypertension, diabetes, BMI, and other traditional risk factors.

The mechanism overlaps with RA: NF-kB activation from sleep deprivation elevates CRP and fibrinogen, both markers of cardiovascular risk. Circadian disruption — whether from shift work, irregular sleep schedules, or untreated sleep apnea — is associated with higher systemic inflammatory load and endothelial dysfunction. Rao's research on how IL-17 and IFN-gamma act synergistically on vascular smooth muscle cells in the coronary arteries illustrates exactly how these cytokines, amplified by sleep loss, can accelerate vascular inflammation [3].

For patients with both RA and elevated cardiovascular risk — a common combination, since RA itself is a cardiovascular risk factor — the implications are compounded.

Sleep apnea: the often-missed driver

Obstructive sleep apnea is particularly important in this context and frequently undiagnosed in RA and cardiac patients. Sleep apnea causes repetitive nocturnal hypoxia, which independently activates NF-kB and drives TNF-alpha elevation through a separate pathway from simple short sleep duration. Studies in sleep apnea patients consistently show elevated TNF-alpha and IL-6, and effective CPAP treatment reduces these inflammatory markers. A patient with RA or heart disease who is sleeping 7 hours but has untreated sleep apnea may still be generating a significant nocturnal inflammatory signal.

What can you do?

The most important step is raising this with your rheumatologist or cardiologist directly. Sleep is not typically part of a standard rheumatology or cardiology visit, but it should be part of disease management planning for patients with ongoing disease activity despite adherence to medication.

Specific questions worth asking:

• "Could poor sleep be contributing to my flares or my elevated inflammatory markers?"
• "Should I be screened for sleep apnea given my disease activity and fatigue levels?"
• "Is my fatigue something you measure as part of my disease activity, or is it being attributed to other causes?"

Beyond the clinical conversation, sleep hygiene is not a soft recommendation in this context — it is a mechanism-based intervention. Consistent sleep and wake times stabilize circadian cortisol rhythms. Avoiding light exposure and screens before bed supports melatonin production, which has its own anti-inflammatory properties. Keeping the sleep environment cool and dark addresses common RA-related barriers to sleep onset.

The bottom line

Sleeping fewer than 6 hours a night activates nuclear factor-kB and drives measurable increases in IL-6, TNF-alpha, and IL-1 beta within 24 to 48 hours — the exact cytokines that RA biologics are designed to suppress. For patients doing everything right on medication but still experiencing disease activity, disrupted sleep may be countermanding their treatment. The same mechanism elevates cardiovascular risk independently of other factors. Rheumatologists and cardiologists rarely screen for sleep quality as a disease modifier, but the research makes a compelling case that they should. If you are adherent to your biologic and still flaring, it is worth asking whether your sleep is part of the picture.